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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal progressive motor neuron disease, for which there are still no
diagnostic/prognostic test and therapy. Specific molecular biomarkers are urgently needed to facilitate clinical studies and
speed up the development of effective treatments.
Methodology/Principal Findings: We used a two-dimensional difference in gel electrophoresis approach to identify in
easily accessible clinical samples, peripheral blood mononuclear cells (PBMC), a panel of protein biomarkers that are closely
associated with ALS. Validations and a longitudinal study were performed by immunoassays on a selected number of
proteins. The same proteins were also measured in PBMC and spinal cord of a G93A SOD1 transgenic rat model. We
identified combinations of protein biomarkers that can distinguish, with high discriminatory power, ALS patients from
healthy controls (98%), and from patients with neurological disorders that may resemble ALS (91%), between two levels of
disease severity (90%), and a number of translational biomarkers, that link responses between human and animal model. We
demonstrated that TDP-43, cyclophilin A and ERp57 associate with disease progression in a longitudinal study. Moreover,
the protein profile changes detected in peripheral blood mononuclear cells of ALS patients are suggestive of possible
intracellular pathogenic mechanisms such as endoplasmic reticulum stress, nitrative stress, disturbances in redox regulation
and RNA processing.
Conclusions/Significance: Our results indicate that PBMC multiprotein biomarkers could contribute to determine
amyotrophic lateral sclerosis diagnosis, differential diagnosis, disease severity and progression, and may help to elucidate
pathogenic mechanisms.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an incurable neurode-
generative disorder of unknown cause arising from progressive
degeneration of motor neurons and resulting in paralysis and
death, usually within 2–4 years from diagnosis. Its incidence is
between 1.5 and 2.5 per 100.000 per year: approximately 90% of
cases are sporadic and the remaining 10% are familial. The
diagnosis is mostly based on clinical assessment with a history of
progression of symptoms and is thus made with a delay of about a
year from symptom onset, quite likely beyond the therapeutic
window of a disease-modifying drug. Moreover, the clinical course
varies widely. No ALS biomarkers are currently in clinical use, but
they would be valuable to support early diagnosis, monitor disease
progression, and assess the efficacy of any new treatment [1].
The pathological process in ALS is now recognized as extending
beyond motorneurons [2–8], so it can be regarded as a multi-cellular/
multi-systemic disease. In particular, peripheral blood mononuclear
cells (PBMC) display traits of the disease such as down-regulation of
Bcl-2 [9,10], increased nitrative stress [11], intracellular calcium
dysregulation [4] and glutamatergic dysfunction [12], suggesting that
they can be a useful source of disease biomarkers.
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may serve as a clinically useful biomarker. Therefore, proteomic
approaches and multiple measurements are likely to be necessary
to identify ALS subjects with a worthwhile degree of accuracy. In
fact, the most promising candidate biomarkers have been so far
combinations of proteins identified in cerebrospinal fluid (CSF)
[13–15]. However, when the same proteins were searched in
plasma either were not present or were not significantly different in
comparison with controls [13,16]. Whereas CSF is considered the
ideal source for identifying biomarkers in neurological diseases
because of its proximity to the affected tissue, it involves an
invasive sampling, that limits large-scale validation studies and
thus introduction into clinical practice. PBMC are readily
accessible clinical samples and offer a series of advantages over
serum/plasma and CSF. Bio-fluids have wide inter-individual
variability and a broad range of protein abundance, which make
them difficult to analyze by proteomic approaches [17,18]. The
cellular proteome is relatively stable, less complex to analyze and
gives direct information on alterations of cellular pathways, hence
insights into possible pathogenic mechanisms.
We here reported a proteome-based strategy to identify and
validate disease biomarkers in PBMC. By using this procedure we
found a panel of proteins that are closely associated with ALS and
have high potential in clinical applications and translational
medicine. Moreover, our results support the use of PBMC of
sporadic ALS (sALS) patients for mechanistic studies.
Results
Proteomic analysis and validation
Figure 1 schematically shows the proteome-based strategy used
to identify and validate protein biomarkers of ALS in PBMC. In
the first phase, PBMC of healthy controls and sALS patients with
two levels of disease severity (Table S1), low, with a ALS functional
rating scale revised (ALSFRS-R) score.24 (ALS.24), and high,
with a ALSFRS-R score#24 (ALS#24), were analyzed by 2D
DIGE (Fig. 1A). The analysis, done with 11 pooled samples for
each group, detected a total of 129 differential protein spots in the
three experimental groups (Table S2). From these spots we used
mass spectrometry to identify 71 corresponding proteins (Fig. 1B)
that were the candidate protein biomarkers (Tables S3, S4). We
classified these proteins in different categories based on their most
recognized function (Table 1). Some of the proteins were identified
in multiple spots, at lower Mw or different pI than the ones
expected (Table S3). These are fragments of the protein or post-
translationally modified isoforms.
We then validated selected proteins by dot blot analysis on
single samples of an independent set of 60 sALS patients, ALS.24
(n=30) and ALS#24 (n=30), and healthy controls (n=30) (Table
S5). From the panel of the candidate biomarkers we validated 12
proteins (PRDX2, GSTO1, CLIC1, HSC70, CypA, PDI, ERp57,
CALR, PA28a, IRAK4, FUBP1, ROA2) for the following reasons:
they are also expressed in the central nervous system (CNS), they
are associated with neurodegenerative processes, some of them
specifically with ALS [11,19–24], and are easily detectable by
commercially available specific antibodies. In the same validation
analysis we also measured actin
NT, whose level was already found
high in PBMC of a small cohort of sALS patients and G93A
SOD1 transgenic rats [11] as well as in the spinal cord of the
G93A SOD1 mouse model of familial ALS [25]; and TDP-43
identified as the major component of ubiquitinated inclusions in
brains of patients with ALS and frontotemporal lobar degenera-
tion [26] and found accumulated in the cytoplasm of PBMC in a
group of ALS patients [27]. We confirmed that all 14 proteins can
significantly distinguish healthy controls from sALS patients
(Fig. 2A, Table 2, Tables S6, S7). As a negative control for the
dot blot assay we used SOD1, that was one of the protein spot that
did not change in the 2D DIGE analysis. Multivariate logistic
analysis showed that CLIC1, actin
NT and ROA2 were the proteins
most associated with ALS in comparison with healthy controls,
with 98% discriminatory power (AUC 0.981) (Fig. 2A). For the
combination of these three proteins, the most convenient cut-off
generated a sensitivity of 91% and a specificity of 96%. In all 60
sALS patients the levels of the 14 protein biomarkers were
independent of sex and age.
CALR, CLIC1, IRAK4, GSTO1 and CypA are ALS-specific
biomarkers
We verified the specificity of the 14 biomarkers with PBMC
samples from patients with neurological disorders that in some
cases may resemble ALS, e.g. some peripheral neuropathies (Table
S8). We analyzed our multiprotein biomarkers by dot blot in
ALS.24 patients (n=20) and controls with neurological disorders
(n=23) (Table 3). Univariate logistic analysis showed that CALR,
CLIC1, IRAK4, GSTO1 and CypA were associated with ALS
(Fig. 2B). Multivariate logistic analysis showed that IRAK4 and
CypA were the proteins most associated with ALS rather than
neurological disorders, with 91% discriminatory power (AUC
0.905) (Fig. 2B). For the combination of these two proteins, the
most convenient cut-off generated a sensitivity of 96% and a
specificity of 79%. It is interesting to note that an equally high level
of TDP-43 was also detected in patients with neurological
disorders (Table 3).
CypA, TDP-43 and ERp57 as biomarkers for disease
progression
We found that CypA, TDP-43 and ERp57 levels significantly
differed in ALS.24 and ALS#24 patients (Figure 3, Table 2),
indicating that these proteins can discriminate between patients
with high and low disease severity. Multivariate logistic analysis
showed that ERp57 was the most associated with more severe
ALS, with 89% discriminatory power (AUC 0.893) (Fig. 3). For
ERp57, a threshold of 2.7 relative immunoreactivity generated a
sensitivity of 93% and a specificity of 70%. We next examined in a
pilot longitudinal study whether CypA, TDP-43 and ERp57
changed over time. We collected three longitudinal PBMC
samples from an independent set of 13 sALS patients over a
period of six months and used a statistical model for repeated
measures to assess the effect of time on protein levels, detected by
dot blot assay. The patients had on average a disease duration of
21610 months, a 3365 ALSFRS-R score at the first draw and a
2867 ALSFRS-R score at the third draw (Table S9). The level of
all the three protein biomarkers showed a significant increase
within six months from the first PBMC collection and for TDP-43
already within 3 months (Fig. 4). As a negative control, in the same
set of samples we measured SOD1, which did not significantly
change over time (Fig. 4).
CypA, GSTO1, FUBP1, CLIC1 and actin
NT are translational
biomarkers of ALS
Translational biomarkers are molecules that can be assessed in
both human and animal models. To test whether our 14 PBMC
proteins were translational biomarkers, their level was measured in
PBMC of a transgenic G93A SOD1 rat model of ALS, at pre-
symptomatic and symptomatic stages of the disease, in comparison
with samples from non transgenic rats by immunoblotting. Five
out of fourteen protein biomarkers, CypA, GSTO1, FUBP1,
ALS Multiprotein Biomarkers in PBMC
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NT, showed similar changes in PBMC of sALS
patients and transgenic rats (Fig. 5). It is interesting to note that
FUBP1 was one of the least specific ALS biomarkers in PBMC of
sporadic patients. It is possible that this protein is more associated
with SOD1 mutation-induced alterations and is more informative
for the mutant SOD1 fALS forms. The translational biomarkers
were also investigated in the rat spinal cord at a presymptomatic
and symptomatic stages of the disease (Fig. 5). Lumbar spinal cords
were sectioned in ventral and dorsal horns to investigate whether
proteins alterations were associated or not with motor neuron
dysfunction and degeneration. In ventral horns, all of them
changed similarly to PBMC already at a presymptomatic stage
except for CLIC1, up-regulated only at a symptomatic stage. In
dorsal horns, the proteins did not change with the progression of
the disease and if compared with controls (Figure S3), indicating
that protein alterations observed in ventral horns are specifically
associated with motor neuron pathology. In conclusion, CypA,
GSTO1, FUBP1, CLIC1 and actin
NT are translational biomark-
ers that might be markers of multi-cellular/multi-systemic
alterations underlining pathogenic events both in the human
sporadic and animal mutant SOD1-linked disease forms.
Discussion
A number of gene expression studies have demonstrated the
utility of PBMC as a source of biomarkers in neurological
disorders [28–30]. This is the first study that describes a highly
feasible strategy to identify and validate multiprotein biomarkers
in PBMC, potentially applicable to several neurological/neurode-
generative diseases. Protein profiles are directly connected to
changes in molecular pathways related to health and disease,
therefore have the potential to accurately monitor the progression
of the disease or the response to a treatment.
We have previously shown that PBMC undergo immunophe-
notypic changes in sALS patients [10]. We have now identified a
panel of protein biomarkers in these cells that are associated with
Figure 1. Proteome-based strategy to identify and validate specific biomarkers of ALS in PBMC. (A) PBMC of healthy controls and sALS
patients with two levels of disease severity, low, ALS.24, or a high one, ALS#24, were analyzed by 2D DIGE. Samples were pooled for analysis (n=11
for each group). The candidate biomarkers, 71 differentially expressed proteins, were identified by mass spectrometry (MS). Validation was done on
14 proteins by dot blot analysis with single samples from an independent set of sALS patients, healthy and non-ALS neurological disorder controls.
We obtained five protein biomarkers that significantly distinguish ALS patients from healthy and non ALS neurological controls and three proteins
that associate with disease progression. The 14 PBMC protein biomarkers were also measured in G93A SOD1 rats: 5 of them were similarly regulated
in the patients and animal model (translational biomarkers). (B) Representative Sypro-Ruby stained 2D gel of the PBMC proteome. The numbered
spots correspond to the differentially expressed proteins listed in Table 1; (C) Validation by dot blot analysis was done with commercially available
antibodies except for the in-house developed anti-actin
NT antibody (Figures S1 and S2). A representative dot blot with the anti-actin
NT antibody and
quantification of the immunoreactive signals are shown. The box-plot shows relative immunoreactivity (IR) in ALS.24 (n=30) (yellow box), ALS 24
(n=30) (red box) patients and healthy controls (n=30) (white box). The bottom and top of the boxes are the lower and upper quartiles, respectively,
the lines inside the boxes indicate the median and the ends of the whiskers represent the minimum and maximum of all the data. *p,0.05 versus
controls as assessed by univariate logistic regression.
doi:10.1371/journal.pone.0025545.g001
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Spot Protein name Uniprot
1
Energy metabolism
1 ATP synthase subunit beta P06576
2 Triosephosphate isomerase P60174
3–6 Phosphoglycerate kinase 1 P00558
7–10 Alpha-enolase Q8WU71
11–13 Fructose-bisphosphate aldolase A P04075
14 Glyceraldehyde-3-phosphate dehydrogenase P04406
15 L- Lactate dehydrogenase A chain P00338
16 L-Lactate dehydrogenase B chain P07195
Redox regulation
17 Flavin reductase P30043
18 Peroxiredoxin-2 (PRDX2)
2 P32119
19 Peroxiredoxin-6 P30041
20 Glutathione S-transferase omega-1 (GSTO1) P78417
21 Superoxide dismutase [Mn] P04179
22 Protein DJ-1 Q99497
23 Chloride intracellular channel protein 1 (CLIC1) O00299
Protein folding and degradation
24–25 Heat shock cognate 71 kDa protein (HSC70) P11142
26 78 kDa glucose-regulated protein P11021
27 Peptidyl-prolyl cis-trans isomerase A (CypA) P62937
28 Protein disulfide-isomerase (PDI) P07237
29–32 Protein disulfide-isomerase A3 (ERp57) P30101
33–34 Endoplasmic reticulum protein ERp29 P30040
35 Calreticulin (CALR) P27797
36 Proteasome activator complex subunit 1 (PA28a) Q06323
Cytoskeleton-associated
37–43 Actin P60709
44–48 Vinculin P18206
49–51 Moesin P26038
52 Tropomyosin alpha-4 chain P67936
53 Alpha-actinin-1 P12814
54–55 Actin-regulatory protein CAP-G P40121
56 F-actin capping protein subunit-alpha 1 P52907
57–58 Talin-1 Q9Y490
59 Transgelin-2 P37802
60 Filamin-A P21333
61 Giantin Q14789
Inflammatory response
62 Group XIIA secretory phospholipase A2 Q9BZM1
63 Annexin A2 P07355
64 Leukocyte elastase inhibitor P30740
65 Interleukin-1 receptor-associated kinase 4 (IRAK4) Q9NWZ3
DNA/RNA binding
66–67 Far upstream element-binding protein 1 (FUBP1) Q96AE4
68 Heterogeneous nuclear ribonucleoproteins A2/B1 (ROA2) P22627
69 Probable ATP-dependent RNA helicase DDX41 Q9UJV9
Others
70 AH receptor-interacting protein O00170
71 Spindle and kinetochore-associated protein 1 Q96BD8
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easily measurable in large-scale immunoassays aimed at develop-
ing diagnostic/prognostic tests for clinical use. The great
advantages of such an in vitro test is low invasiveness for the
patient compared to CSF tests, the consequent greater availability
of samples for large clinical studies, including longitudinal ones,
and the simple laboratory procedures involved.
The ideal diagnostic marker should detect disease before
clinical diagnosis, which is highly challenging for a rare and
sporadic disease. ALS patients very often see the specialized
neurologist only months after the first symptoms, when they are
unquestionably ill. It is therefore very difficult to test and validate
the applicability of biomarkers in preclinical diagnosis. Our
PBMC protein biomarkers seems to be promising to support
prompt clinical diagnosis, since all the 14 validated proteins can
distinguish with high significance ALS patients with low disability
from healthy controls (Table S6). PBMC biomarkers could be
measured on patients after as early as 5 months up to 108 months
from symptom onset, and with high (from 45) and low (up to 10)
ALSFRS-R scores (Table S5, S8, S9). Now large-scale validations
are needed, in which data will be verified in a prospective cohort
with analysis of the biomarkers at the time of symptom
presentation. In the G93A SOD1 rat model of ALS, alterations
of the level of CypA, GSTO1, FUBP1, CLIC1 and actin
NT are
detected before disease onset. It is possible that some of these
biomarkers may predict the onset of SOD1-linked familial ALS.
This potential application will be also considered in future
analysis.
Figure 2. Validation of the 14 selected protein biomarkers versus healthy controls and non-ALS neurological controls: statistical
analysis. Validation on single PBMC samples from ALS patients, healthy and non-ALS neurological controls was done by dot blot analysis. Receiver
operating characteristics (ROC) curves and analysis of the area under the curve (AUC) were used to find the discriminatory power for proteins
showing a significant association with ALS (A,C) or with disease severity (B). Results were expressed as odds ratios (OR) and 95% confidence intervals
(95% CI). A 95% CI not including the value of 1 indicates a statistically significant result. All probability values were two-sided and p,0.05 was
considered significant. (A) Univariate logistic regression: healthy controls (n=30) versus ALS, ALS.24 (n=30) and ALS#24 (n=30). All 14 proteins
were significantly associated with ALS (p values in bold type). CLIC1, actin
NT and ROA2 were significant in multivariate analysis (highlighted in grey): a
ROC curve for the combination of the three proteins and relative AUC is shown; (B) Univariate logistic regression: ALS.24 (n=20) versus non-ALS
neurological controls (n=23). CALR, CLIC1, IRAK4, GSTO1, CypA had significant associations with ALS (in bold type). IRAK4 and CypA were significant
in multivariate analysis (highlighted in grey): a ROC curve for the combination of the two proteins and relative AUC is shown.
doi:10.1371/journal.pone.0025545.g002
Table 1. Cont.
Fold changes and mass spectrometry data are reported in Tables S3, S4.
1Entry from the Uniprot Knowledgebase database;
2In bold are the proteins selected for further validations.
doi:10.1371/journal.pone.0025545.t001
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false positive [31,32]. A similar percentage is false negative and
undergoes inappropriate medical or surgical procedures [33,34].
Thus, there is a need for biomarkers that distinguish ALS with
high accuracy from neurological disorders that in some cases may
resemble it, e.g. some peripheral neuropathies that are treatable
and do not have a fatal prognosis. We found that there are PBMC
protein biomarkers that significantly distinguish ALS from the
group of neurological disorders considered in our study. These are
chaperones (CALR, CypA), proteins involved in redox homeosta-
sis (GSTO1, CLIC1) and immune responses (IRAK4). IRAK4,
which has no previous association with ALS, has a central function
in innate immunity [35].
Finally, multivariate analysis helped us in defining the most
convenient combination of protein biomarkers that could be
potentially used in clinics (i) to support diagnosis (CLIC1, actin
NT
and ROA2), (ii) to contribute to differential diagnosis of ALS from
other neurological conditions (CypA and IRAK4), and (iii) to
determine disease severity (ERp57).
There are no precise measures of ALS disease progression that
allow for short-term monitoring of the disease and assessment of
treatment efficacy. In clinical trials survival time is therefore used
as the primary measure of outcome. This requires large number of
patients followed over a long period of time making ALS clinical
trials very expensive. A panel of biomarkers that can reliably assess
disease progression would enable a substantial reduction of the
costs of the clinical trial and accelerate therapy development in
ALS. ERp57, CypA and TDP-43, that were able to discriminate
between patients with high and low disease severity, were selected
for a pilot longitudinal study and proved to be good candidates for
such applications. Large longitudinal studies are now needed to
further validate the use of these proteins in clinical practice.
The pathogenesis of sALS is largely unknown. The concept of
PBMC as a window into the CNS has been already proposed for
several neurological disease states [28–30,36,37]. CNS and
immune cells communicate through multiple mechanisms and
have several similarities in receptor expression and transduction
processes [38]. We therefore hypothesized that PBMC protein
Table 2. Validation of 14 selected protein biomarkers in patients and healthy controls.
Protein controls ALS.24 ALS#24 ALS.24 vs controls* ALS#24 vs controls* ALS#24 vs ALS.24*
CALR 2.860.7 4.962.8 4.462.3 1.8 1.6 21.1
TDP-43 4.161.6 5.262.1 6.862.6 1.3 1.7 1.3
PRDX2 0.960.5 1.460.7 2.061.1 1.6 2.2 1.4
PDI 1.060.3 1.660.7 1.860.7 1.6 1.8 1.1
ERp57 2.560.7 3.861.4 4.762.4 1.5 1.9 1.2
PA28a 4.164.5 1.461.1 1.661.6 22.9 22.6 1.1
CLIC1 0.460.3 0.860.4 0.960.5 2.0 2.3 1.1
IRAK4 1.060.5 2.261.5 2.461.5 2.2 2.4 1.1
FUBP1 1.761.5 0.660.6 0.961.0 22.8 21.9 1.5
GSTO1 1.260.7 0.760.5 0.660.4 21.7 22.0 21.2
HSC70 0.860.5 1.761.2 2.362.3 2.1 2.9 1.4
CypA 1.460.7 3.462.7 2.061.2 2.4 1.4 21.7
Actin
NT 0.760.3 1.560.8 1.660.6 2.1 2.3 1.1
ROA2 2.961.8 5.762.7 6.463.0 2.0 2.2 1.1
SOD1 0.360.1 0.360.2 0.360.1 1.0 1.0 1.0
Validation was done by dot blot assay with the specific antibodies on single PBMC samples from ALS patients, ALS.24 (n=30) and ALS#24 (n=30), and healthy
controls (n=30); mean 6 SD of the relative immunoreactivity of the specific antibody normalized to the actual amount of proteins loaded on the membrane as
detected after Red Ponceau staining;
*, -fold change as the mean increase (positive) and decrease (negative) in protein concentration in samples from ALS patients in comparison with healthy controls or
between the two levels of disease severity.
doi:10.1371/journal.pone.0025545.t002
Table 3. Validation of the 14 biomarkers in patients and non-
ALS neurological controls.
Protein controls ALS.24 ALS.24 vs NC*
CALR 4.962.8 3.261.3 21.5
TDP-43 2.260.6 2.060.5 21.1
PRDX2 0.560.2 0.660.2 1.2
PDI 0.960.4 0.860.4 21.1
ERp57 0.160.1 0.160.1 1.0
PA28a 0.360.2 0.360.2 1.0
CLIC1 2.962.1 1.560.8 21.9
IRAK4 0.760.2 1.060.4 1.4
FUBP1 2.061.3 2.862.0 1.4
GSTO1 0.860.6 0.560.3 21.6
HSC70 3.462.6 2.362.2 21.5
CypA 4.562.2 2.661.0 21.7
Actin
NT 2.861.3 3.061.2 1.1
ROA2 1.960.9 1.761.0 21.1
Validation was done by dot blot assay with the specific antibodies on single
PBMC samples from ALS patients, ALS.24 (n=20), and non-ALS neurological
controls (NC) (n=23); mean 6 SD of the relative immunoreactivity of the
specific antibody normalized to the actual amount of proteins loaded on the
membrane as detected after Red Ponceau staining;
*, -fold change as the mean increase (positive) and decrease (negative) in
protein concentration in samples from ALS patients in comparison with
neurological controls.
doi:10.1371/journal.pone.0025545.t003
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Indeed, some of the protein biomarkers identified in PBMC of
sALS patients were previously found as hallmarks of disease in
CNS. Studies in spinal cord tissues of sALS patients showed that
PDI and ERp57 were up-regulated [20], CypA and HSC70 were
accumulated in the detergent-insoluble fraction [39], HSC70 was
present in hyaline inclusions [24], and TDP-43 was identified as
the major component of the ubiquitinated inclusions [26].
The protein profile changes detected in PBMC of ALS patients
are suggestive of possible pathogenic mechanisms. For instance,
up-regulation of endoplasmic reticulum (ER) chaperones (PDI,
ERp57, CALR) is a typical cellular response to ER stress that
triggers the unfolded protein response leading eventually to cell
death [40]. The increased level of a nitrotyrosine-linked protein,
actin
NT, is indicative of nitrative stress [41]. Alterations in CypA,
GSTO1, PRDX2 suggest disturbances in cellular redox regulation
[42–45]. It is important to note that all these pathogenic
alterations were previously reported in the spinal cord of sALS
patients and mutant SOD1 animal models [19,20,25,46–49].
ROA2 belongs to the family of heterogeneous nuclear ribonu-
cleoproteins that participates to several RNA-related biological
processes such as transcription, pre-mRNA processing, mRNA
transport to the cytoplasm and translation [50]. It is also a binding
partner of TDP-43 and seems to be crucial for at least one of its
putative functions [51]. The up-regulation of ROA2 and TDP-43
in PBMC of both ALS.24 and ALS#24 patients may underline
aberrant RNA processing events that are now emerging as central
in ALS and other neurological disorders [52]. These specific
Figure 3. Protein biomarkers that associate with disease severity. Analyses of the 14-protein biomarkers were done on single PBMC samples
from ALS patients, ALS.24 (n=30) and ALS#24 (n=30), by dot blot analysis. ROC curves and analysis of the area under the curve (AUC) were used to
find the discriminatory power for proteins showing a significant association with disease severity. Results were expressed as odds ratios (OR) and 95%
confidence intervals (95% CI). A 95% CI not including the value of 1 indicates a statistically significant result. All probability values were two-sided and
p,0.05 was considered significant. Univariate logistic regression: TDP-43, ERp57 and CypA gave a significant association with disease severity (in bold
type). Multivariate analysis indicated that ERp57 was the protein most closely associated with disease severity (highlighted in grey). A ROC curve for
ERp57 is shown.
doi:10.1371/journal.pone.0025545.g003
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25545intracellular alterations would not be detectable from the protein
profiles of CSF or plasma. Neuroinflammation, which is
characterized by activated microglia and infiltrating peripheral
blood immune cells, is a prominent pathological feature in ALS
[53]. It is possible to speculate that such consistent protein profile
changes in immune cells may influence their infiltration and/or
interaction with microglia and neurons, thus upsetting the delicate
balance between neuroprotection and neurotoxicity. In summary,
all these data endorse the use of PBMC for further in vitro
mechanistic studies. Experimental models for the sporadic form
are not available and all mechanistic studies are done with
transgenic cells and animals expressing one of the mutant genes
linked to familial ALS. Studies with PBMC would have the
advantage to consider the influence of the genetic background of
the patient.
Translational biomarkers, that link responses between human
and animal model, are of particular interest because their role in
the pathogenesis can be investigated in detail in the animal model
where they can also offer important preliminary information for
clinical trials. We found that CypA, GSTO1, FUBP1, CLIC1 and
actin
NT are translational biomarkers. Moreover, all of them except
for CLIC1 are altered in the ventral horn spinal cord of SOD1
G93A rats before disease onset, suggesting a possible involvement
in pathways that trigger the disease. Further mechanistic studies in
the animal models with these proteins are now warranted.
In conclusion, we identified and verified a panel of highly
promising protein biomarkers of ALS in PBMC that may be useful
in clinical studies, helping elucidate pathogenic mechanisms and
pin-pointing pathways to tackle for future therapeutic interven-
tions. The fact that our protein biomarkers are easily measurable
in accessible clinical samples using straightforward immunoassays
makes them attractive candidates for true multi-centric large-scale
validations and eventually introduction into clinical practice.
Materials and Methods
Subjects
The study was approved by the Ethical Committees of all the
Centers involved in the study, IRCCS Fondazione S. Maugeri, in
Milano and Pavia, NEMO-Niguarda Ca’ Granda Hospital,
Milano, and Transfusion Medical Centre at the IRCCS Policlinico
S. Matteo, Pavia, and written informed consent was obtained from
all participating subjects. In this study we included 94 sALS
patients and 64 controls (41 healthy, 23 with non-ALS
neurological disorders). Patients with definite ALS, according to
revised El Escorial criteria, were examined and blood samples
were collected at the IRCCS Fondazione S. Maugeri, in Milano
and Pavia, Italy. To evaluate the level of disability of the patients
the ALSFRS-R score was used [54]. The patients were arbitrary
divided into two groups according to the ALSFRS-R score, .24
or #24. None of the sALS patients had systemic inflammatory
conditions as detected by the erythrocyte sedimentation rate and
total blood cell count. Sixty-five percent of the patients were
treated with riluzole. For the longitudinal study PBMC samples
were collected every three months over a period of six months at
the NEMO, Niguarda Ca’ Granda Hospital. Blood samples of
non-ALS neurological disorder controls were provided by the
NEMO and the IRCCS Fondazione S. Maugeri, in Milano and
Pavia. None of the patients was receiving drugs that might
interfere with total blood cell count. The characteristics of ALS
Figure 4. Longitudinal analysis of protein biomarkers CypA, ERp57 and TDP-43. Graphs show relative immunoreactivity (IR) for the
indicated proteins measured by dot blot assay in PBMC of sALS patients (n=13) over a period of six months. PBMC were collected at t=0 (T1, white
column), at t=3 months (T2, grey column) and at t=6 months (T3, black column). SOD1 was used as a negative control. Immunoreactivity was
normalized to the actual amount of protein loaded, detected after Red Ponceau staining. Data are the means 6 SEM of relative immunoreactivity.
*, significantly different (p,0.05) from T1 as assessed by repeated measures ANOVA followed by Tukey’s multiple comparison test; #, significantly
different (p,0.05) from T2 as assessed by repeated measures ANOVA followed by Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0025545.g004
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described in Tables S1, S5, S8 and S9. Blood samples of healthy
donors were provided by the Transfusion Medical Centre at the
IRCCS Policlinico S. Matteo, Pavia.
PBMC
Samples of peripheral venous blood from patients and controls
were collected in EDTA pre-coated vials (Vacuette K3E
K3EDTA, Greiner bio-one). PBMC were isolated from EDTA-
blood by Ficoll-Hypaque (Ficoll-Plaque
TM Plus, GE Healthcare)
density gradient centrifugation. Mononuclear cells were harvested
from the interface and washed three times with RPMI 1640
medium (EuroClone). Platelets were eliminated by an additional
wash and centrifugation at 2006 g for 10 min. Patients’ and
controls’ PBMC were stored as pellets at 280uC. Just before
analysis PBMC proteins were obtained by cell lysis in 20 mM Tris-
HCl pH 7.5, 0.1% NP40 and 0.1% SDS supplemented with
Protease Inhibitors (Sigma). Proteins were quantified by the BCA
protein assay (Pierce).
Two-dimensional difference in gel electrophoresis (2D
DIGE)
PBMC proteins were prepared for 2D DIGE analysis. Three
pools of 25 mg from 11 healthy controls, 11 ALS.24 and 11
ALS#24 patients were methanol-precipitated. Proteins were then
dissolved in 30 mM Tris-HCl pH 8.5, 7 M urea, 2 M thiourea,
Figure 5. Analysis of protein biomarkers in the G93A SOD1 transgenic rat model: comparison with sALS patients. Human PBMC (left
column): box-plot shows relative immunoreactivity for the indicated proteins measured by dot blot assay in ALS.24 (n=30) (grey box) and ALS#24
(n=30) (dark grey box) patients as percentage of healthy controls (control) (n=30) (white box). *, significantly different (p,0.05) from control
(univariate logistic regression). Rat PBMC (middle column): box-plot shows relative immunoreactivity for the indicated proteins measured by WB
(except for actin
NT, measured by dot blot) in PBMC lysates (15 mg) of presymptomatic (pres) (n=6) and symptomatic (symp) G93A SOD1 (n=6) rats as
percentage of non transgenic (control) (n=8) rats. Protein level values were normalized to actin loading control. *, significantly different (p,0.05)
from controls (one-way ANOVA followed by Newman-Keuls multiple comparison test). Rat spinal cord (right column): box-plot shows relative
immunoreactivity for the indicated proteins measured by dot blot in ventral horn tissue lysates of presymptomatic (pres) (n=6) and (symp) G93A
SOD1 (n=6) rats as percentage of non transgenic (control) (n=8) rats. Immunoreactivity was normalized to the actual amount of protein loaded,
detected after Red Ponceau staining. *, significantly different (p,0.05) from control (one-way ANOVA followed by Newman-Keuls multiple
comparison test).
doi:10.1371/journal.pone.0025545.g005
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turer’s instructions (GE Healthcare) with minor modifications.
Briefly, 25 mg of each pool was labeled with 200 pmol of Cy3 or
Cy5 dye for 30 min in ice in the dark. To exclude preferential
labeling of the dyes, each sample was also reverse labeled. As an
internal standard, aliquots of each pool were mixed and labeled
with Cy2 dye. Labeled samples were then resuspended in Destreak
Solution
TM (GE Healthcare) with IPG buffer pH 3–10 NL 0.5%
v/v (GE Healthcare) added and loaded into 7 cm-IPG strips pI
range 3–10NL (GE Healthcare). Isoelectrofocusing was done on
an IPGphor apparatus (GE Healthcare) with the following
protocol: 30 V for 270 Vhrs, 200 V for 200 Vhrs, 2000 V for
2000 Vhrs, a linear gradient of 3500 V for 1375 Vhrs, 3500 V for
7000 Vhrs, a linear gradient of 8000 V for 8625 Vhr, 8000 V for
32000 Vhr and forever at 30 V. SDS-PAGE was done using
precast 10% polyacrylamide SDS gel (Invitrogen). Four 2D gels
were run with the three experimental groups: healthy controls and
ALS patients, ALS.24, and ALS#24. Each gel contained two
experimental groups, one Cy3-labelled, the other Cy5-labelled
plus the Cy2-labelled internal standard. Gel images were captured
by the laser scanner Molecular Imager FX (Bio-Rad). Image
analysis was done with Progenesis PG240 v2006 software
(Nonlinear Dynamics). For each spot the normalized volume was
standardized against the intra-gel standard, dividing the value for
each spot normal volume by the corresponding internal standard
spot normal volume within each gel. The values for each spot in
each group were expressed as the mean of the Cy3- and Cy5-
labelled analyses. The values for ALS patients were reported as
fold change: higher (positive) or lower (negative) spot volume of the
samples from ALS patients in comparison with healthy controls
(Table S4).
Protein identification
Protein spots were located and excised from 2D gels with the
EXQuest
TM spot cutter (Bio-Rad). Spots were processed and gel-
digested with modified trypsin from bovine pancreas (Roche) and
identified by mass spectrometry (MS), essentially as previously
described [25]. Digestion, desalting and concentration with
ZipTipH pipette tips with C18 resin (Millipore) and MALDI
target deposition were carried out on an automated protein
digestor DigestPro MS (Intavis AG). Peptide mass fingerprinting
and tandem mass spectrometry (MS/MS) were done on a 4800
MALDI TOF/TOF mass spectrometer (Applied Biosystems). The
mass spectra were internally calibrated with trypsin autolysis
fragments. The five most abundant precursor ions, out of the
exclusion mass list (ions from human keratin and trypsin), were
selected for MS/MS analysis. The combined MS and MS/MS
data were submitted by GPS Explorer v.3.6 software (Applied
Biosystems) to the MASCOT database search engine (Version 2.1,
Matrix Science) and searched with the following parameters:
Uniprot_Swissprot 57.8 database over all Homo sapiens protein
sequences deposited, no fixed modifications, as possible modifica-
tions carboamidomethylation of cysteine and oxidation of
methionine, 1 missed trypsin cleavage, a mass tolerance of
60.1 Da for the peptide masses and 60.3 Da for the MS/MS
fragment ion masses. A protein was regarded as identified if the
MASCOT protein score, based on the combined MS and MS/
MS data, was above the 5% significance threshold for the database
[55]. Some of the proteins were identified by liquid chromatog-
raphy-(LC)-MS/MS using the microfluid chip-based technology
for nanoelectrospray coupled to an ion trap mass spectrometer
(Agilent 1200 LC/MSD Trap XCT) as previously described [56].
Data were acquired sequentially in MS mode (scan range 200–
2000 amu) and in data-dependent mode, automatically recording
the MS/MS spectra of the four most abundant ions in every scan
cycle. Data files of all MS/MS spectra in a LC run were merged,
and submitted as an ‘‘mgf’’ file (BioWorks Rev 3.1 SR1, Thermo
Scientific) to the MASCOT database search engine in MS/MS
Ion Search mode. A protein was regarded as identified if
MASCOT individual ion scores were .36, which indicate identity
or extensive homology (p,0.05), for at least three matched
peptides. Search parameters were the same as above.
Anti-nitrated actin (actin
NT) antibody preparation
Purified human non-muscle actin (.99% pure; Cytoskeleton,
Inc.) (1.5 mg/mL) was incubated for 24 hours at room temper-
ature in a nitration solution containing 20 mM sodium acetate
pH 5.6, 9 mM FeCl3, 10 mM NaNO2, 0.3% H2O2. Nitration of
the protein was verified by Western blotting (WB) with the anti-
nitrotyrosine antibody (clone HM.11; Hycult Biotechnology).
Actin
NT was used as antigen in rabbits for raising polyclonal
antibodies at Eurogentec S.A. LIEGE Science Park (Belgium).
Anti-actin
NT antibody was characterized as described in Figures
S1 and S2.
Dot blot analysis
Aliquots (3 mg) of PBMC samples were loaded on nitrocellulose
membrane, Trans-Blot Transfer Medium (Bio-Rad), by vacuum
deposition on the Bio-Dot SF blotting apparatus (Bio-Rad).
Membranes were probed overnight with primary antibodies:
rabbit polyclonal anti-CALR (1:5000), rabbit polyclonal anti-PDI
(1:4000) and mouse monoclonal anti-ERp57 (1:500) from Stress-
Gen, mouse monoclonal anti-HSC70 (1:1000), goat polyclonal
anti-PRDX2 (1:2000), goat polyclonal anti-PA28a (1:2000), mouse
monoclonal anti-CLIC1 (1:2500), goat polyclonal anti-IRAK4
(1:1000) and rabbit polyclonal anti-FUBP1 (1:1000) from Santa
Cruz Biotechnology, mouse monoclonal anti-GSTO1 (1:500) and
mouse monoclonal anti-ROA2 (1:2500) from Abnova, rabbit
polyclonal anti-CypA (1:2500) and rabbit polyclonal anti-hSOD1
(1:2000) from Upstate Biotechnology, rabbit polyclonal anti-
actin
NT (1:7500) developed in-house, and rabbit polyclonal anti-
TDP-43 (1:2000), kindly provided by Francisco Baralle, ICGEB,
Trieste, Italy, and then with secondary anti-mouse, anti-rabbit or
anti-goat peroxidase-conjugated secondary antibodies (Santa Cruz
Biotechnology). Blots were developed by Immobilon Western
Chemiluminescent HRP Substrate (Millipore) on the ChemiDoc
XRS system (Bio-Rad). Densitometry was done with Progenesis
PG240 v2006 software (Nonlinear Dynamics). Immunoreactivity
was normalized to the actual amount of proteins loaded on the
membrane as detected after Red Ponceau staining (Fluka).
Statistical analysis
Continuous variables such as age and all data of the considered
proteins were described using ‘standard’ statistics (mean, standard
deviation), and relative and absolute frequencies were used for
categorical variables. Spearman correlation analysis was done to
assess the associations between the 14 proteins. Univariate and
multivariate logistic regression models were also built to identify
the level of association between proteins and ALS patients.
Receiver operating characteristics (ROC) curves and analysis of
the area under the curve (AUC) were used to find the
discriminatory power for proteins showing a significant association
with ALS or disease severity. Results were expressed as odds ratios
(OR) and 95% confidence intervals (95% CI). A 95% CI not
including the value of 1 indicates a significant result. Dependence
on sex and age (at the time of PBMC collection) was analyzed by
two-way ANOVA. All probability values were two-sided and
p,0.05 was considered statistically significant. Version 9.1 of the
ALS Multiprotein Biomarkers in PBMC
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version 5.03 of the GraphPad Prism software (GraphPad Software,
Inc, La Jolla, CA, USA) were used.
Analysis of protein biomarkers in the rat model
Procedures involving animals and their care were conducted in
conformity with the institutional guidelines that are in compliance
with national (D.L. No. 116, Suppl. 40, Feb. 18, 1992 Circolare
No. 8, G.U., 14 luglio 1994) and International laws and policies
(EEC Council Directive 86/609. OJ L 358,1, Dec. 12, 1987; NIH
Guide for Care and use of Laboratory Animals, U.S. National Research
Council, 1996). They were reviewed and approved by the Mario
Negri Institute Animal Care and Use Committee that includes ad
hoc members for ethical issues (ID 33/01-D Appl3). Non
transgenic and transgenic rats expressing a high copy number of
mutant human SOD1 with Gly-93-Ala substitution were bred and
maintained at the Mario Negri Institute for Pharmacological
Research, Milan, Italy. Animals were housed at 2161uC with
relative humidity 55610% and 12 h of light. Food (standard
pellets) and water were supplied ad libitum. Transgenic rats were
identified with PCR on DNA from tail biopsies. G93A SOD1 rats
were sacrificed at presymptomatic (15 weeks of age) and early-
symptomatic (20 weeks of age) stages of disease. Non transgenic
rats were used as controls (20 weeks of age). Blood was sampled
directly by intracardiac puncture from rats and collected in EDTA
pre-coated vials (Vacuette K3E K3EDTA, Greiner bio-one).
PBMC were isolated from blood, washed and stored as pellets at
280uC in the same way as the human samples. PBMC proteins
were obtained by cell lysis in 50 mM Tris-HCl, pH 7.5, 2% (w/v)
CHAPS, 37.5 U benzonase (Merck), supplemented with Protease
Inhibitors (Sigma). Proteins were quantified by the BCA protein
assay (Pierce). Proteins were separated by SDS-PAGE on precast
12% Criterion XT Bis-Tris gels (Bio-Rad) and immunoblotted, as
described [39]. The blots were probed with primary and
secondary antibodies, as described for dot blot assay of the human
samples. Blots were also probed with an antibody that recognizes
actin (mouse monoclonal, 1:1000 dilution, Chemicon) for loading
control and developed by Immobilon Western Chemiluminescent
HRP Substrate (Millipore) on the ChemiDoc XRS system (Bio-
Rad). Densitometry was done with Progenesis PG240 v2006
software (Nonlinear Dynamics). Spinal cords were removed and
the lumbar tract was cut into ventral and dorsal horn sections on a
cryostat. Ventral and dorsal horn sections were suspended in 1%
SDS (5 mL/mg), sonicated and boiled for 10 min. Homogenates
were centrifuged at 12000 RPM and supernatants analyzed by dot
blot, as described for the human samples except for the FUBP1
and PA28a analyses where the mouse monoclonal anti-FUBP1
antibody (1:500) from Santa Cruz Biotechnology and the rabbit
polyclonal anti-PA28a antibody (1:1000) from Cell Signaling were
used.
Supporting Information
Figure S1 Anti-nitrated actin (actin
NT) antibody prepa-
ration and characterization by dot blot assay. Purified
human actin was nitrated in vitro and used as antigen in rabbits for
raising polyclonal antibodies. The rabbit polyclonal antiserum was
tested by dot blot with actin, actin
NT, bovine serum albumin (BSA)
and BSA
NT, prepared by the same procedure as actin
NT. Figure
S1 shows that anti-actin
NT does not efficiently recognize another
nitrated protein and has more than three times affinity for actin
NT
of unmodified actin. 3 mg of actin, actin
NT, BSA and BSA
NT were
loaded in each slot on the nitrocellulose membrane. The
membrane was probed overnight with the polyclonal antiserum
diluted 1:7500. Immunoreactivity was normalized to the actual
amount of protein loaded on the membrane as detected after Red
Ponceau staining.
(TIF)
Figure S2 Characterization of the anti-actin
NT anti-
body. The anti-actin
NT antibody was further characterized to
determine the specificity of the immunoreactivity against PBMC
lysates from controls and ALS patients by Western blotting. Figure
S2 shows that the antiserum recognized a band at 42 kDa, which
is the expected Mw for actin
NT, but also other bands at higher
Mw. These are probably polymerized actin forms. These high-Mw
species are essentially only detected in the patients and make this
antibody especially useful to distinguish ALS patients from
controls, also in a dot blot assay, as shown in Figure 1. Equal
amounts of PBMC lysates (30 mg) from healthy controls and ALS
patients were analyzed. A representative experiment is shown. The
PVDF membrane was probed first with the anti-actin antibody
(mouse monoclonal, 1:1000 dilution, Chemicon), and the signal
was revealed with a goat anti-mouse QdotH 800-conjugated
secondary antibody (Invitrogen, 1:1000 dilution) on a laser scanner
Molecular Imager FX (Bio-Rad), then with the anti-actin
NT
antibody, and the signal was revealed with an anti-rabbit
peroxidase-conjugated secondary antibody/chemiluminescent
HRP Substrate (Millipore) on a ChemiDoc XRS system (Bio-
Rad).
(TIF)
Figure S3 Analysis of protein biomarkers in dorsal horn
spinal cord of the G93A SOD1 transgenic rat. Bars show
relative immunoreactivity for the indicated proteins measured by
dot blot in ventral horn tissue lysates of presymptomatic (pres, grey
bars) (n=6) and (symp, dark grey bars) G93A SOD1 (n=6) rats
and non transgenic (control, white bars) (n=8) rats. Immunore-
activity was normalized to the actual amount of protein loaded,
detected after Red Ponceau staining. None of the protein levels
were significantly different from control (one-way ANOVA
followed by Newman-Keuls multiple comparison test).
(TIF)
Table S1 Main characteristics of healthy individuals
and sALS patients used in the proteomic 2D DIGE
analysis.
(DOC)
Table S2 Spot volume changes in 2D DIGE analysis.
(DOC)
Table S3 Candidate protein biomarkers identified by
mass spectrometry.
(DOC)
Table S4 Candidate protein biomarkers: 2D DIGE
quantitative analysis.
(DOC)
Table S5 Main characteristics of healthy individuals
and sALS patients used for the validation analysis
(Figure 2A and Figure 3).
(DOC)
Table S6 Univariate logistic regression: controls versus
ALS.24.
(DOC)
Table S7 Univariate logistic regression: controls versus
ALS#24.
(DOC)
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neurological controls used for the validation analysis
(Figure 2B).
(DOC)
Table S9 Characteristics of sALS patients used for the
longitudinal study (Figure 4).
(DOC)
Acknowledgments
We are grateful to individuals who participated in the study and to Cesare
Perotti at the Transfusion Medical Centre, IRCCS Policlinico San Matteo,
Pavia, Italy, and numerous unnamed staff also at the IRCSS Fondazione S.
Maugeri, in Pavia and Milano, Italy, and at the NEMO, Niguarda Ca’
Granda Hospital, Milano, Italy, for collecting blood samples. We also
thank Donatella Carpi, Roberta Campagna and Renzo Bagnati for
assistance in mass spectrometric analysis, Francisco Baralle for the anti-
TDP-43 antibody, and Judith Baggott for editorial assistance. We thank the
Tolomio and Boldrin families and their friends at Liceo Galilei, Dolo, and
Ciba Vision for the donation in memory of Giuseppe Boldrin.
Author Contributions
Conceived and designed the experiments: VB CB GM MC CL. Performed
the experiments: GN SP MP EL GS SG SM. Analyzed the data: GN MM
VT L. Paris GB CL MC GM CB VB. Wrote the paper: VB. Enrolled
patients and collected blood samples: KM L. Papetti CL.
References
1. Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in
amyotrophic lateral sclerosis. Lancet Neurol 8: 94–109.
2. Aguirre T, Van Den Bosch L, Goetschalckx K, Tilkin P, Mathijs G, et al. (1998)
Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to
oxidative stress. Ann Neurol 43: 452–457.
3. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, et al. (2003)
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in
ALS mice. Science 302: 113–117.
4. Curti D, Malaspina A, Facchetti G, Camana C, Mazzini L, et al. (1996)
Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium
homeostasis in peripheral blood lymphocytes. Neurology 47: 1060–1064.
5. Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, et al. (2008)
Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab
8: 425–436.
6. Ono S (2000) The skin in amyotrophic lateral sclerosis. Amyotroph Lateral Scler
Other Motor Neuron Disord 1: 191–199.
7. Wong M, Martin LJ (2010) Skeletal Muscle-Restricted Expression of Human
SOD1 Causes Motor Neuron Degeneration in Transgenic Mice. Hum Mol
Genet 19: 2284–2302.
8. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, et al. (2006) Wild-type
microglia extend survival in PU.1 knockout mice with familial amyotrophic
lateral sclerosis. Proc Natl Acad Sci U S A 103: 16021–16026.
9. Cova E, Cereda C, Galli A, Curti D, Finotti C, et al. (2006) Modified expression
of Bcl-2 and SOD1 proteins in lymphocytes from sporadic ALS patients.
Neurosci Lett 399: 186–190.
10. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, et al. (2009) Immune
system alterations in sporadic amyotrophic lateral sclerosis patients suggest an
ongoing neuroinflammatory process. J Neuroimmunol 210: 73–79.
11. Nardo G, Pozzi S, Mantovani S, Garbelli S, Marinou K, et al. (2009)
Nitroproteomics of peripheral blood mononuclear cells from patients and a rat
model of ALS. Antioxid Redox Signal 11: 1559–1567.
12. Poulopoulou C, Davaki P, Koliaraki V, Kolovou D, Markakis I, et al. (2005)
Reduced expression of metabotropic glutamate receptor 2mRNA in T cells of
ALS patients. Ann Neurol 58: 946–949.
13. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, et al. (2010) Combination
of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.
J Neurochem.
14. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, et al.
(2009) A CSF biomarker panel for identification of patients with amyotrophic
lateral sclerosis. Neurology 72: 14–19.
15. Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, et al. (2006)
Identification of potential CSF biomarkers in ALS. Neurology 66: 1218–1222.
16. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR (2010) Plasma
biomarkers associated with ALS and their relationship to iron homeostasis.
Muscle Nerve 42: 95–103.
17. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM (2005)
Comparative proteomic analysis of intra- and interindividual variation in
human cerebrospinal fluid. Mol Cell Proteomics 4: 2000–2009.
18. Zhang J (2007) Proteomics of human cerebrospinal fluid - the good, the bad, and
the ugly. Proteomics Clin Appl 1: 805–819.
19. Atkin JD, Farg MA, Turner BJ, Tomas D, Lysaght JA, et al. (2006) Induction of
the unfolded protein response in familial amyotrophic lateral sclerosis and
association of protein-disulfide isomerase with superoxide dismutase 1. J Biol
Chem 281: 30152–30165.
20. Atkin JD, Farg MA, Walker AK, McLean C, Tomas D, et al. (2008)
Endoplasmic reticulum stress and induction of the unfolded protein response
in human sporadic amyotrophic lateral sclerosis. Neurobiol Dis 30: 400–407.
21. Kato S, Kato M, Abe Y, Matsumura T, Nishino T, et al. (2005) Redox system
expression in the motor neurons in amyotrophic lateral sclerosis (ALS):
immunohistochemical studies on sporadic ALS, superoxide dismutase 1
(SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta
Neuropathol 110: 101–112.
22. Massignan T, Casoni F, Basso M, Stefanazzi P, Biasini E, et al. (2007) Proteomic
analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A
SOD1 mouse. Biochem Biophys Res Commun 353: 719–725.
23. van de Giessen E, Fogh I, Gopinath S, Smith B, Hu X, et al. (2008) Association
study on glutathione S-transferase omega 1 and 2 and familial ALS. Amyotroph
Lateral Scler 9: 81–84.
24. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, et al. (2001)
Histological evidence of protein aggregation in mutant SOD1 transgenic mice
and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933–941.
25. Casoni F, Basso M, Massignan T, Gianazza E, Cheroni C, et al. (2005) Protein
nitration in a mouse model of familial amyotrophic lateral sclerosis: possible
multifunctional role in the pathogenesis. J Biol Chem 280: 16295–16304.
26. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al.
(2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Science 314: 130–133.
27. De Marco G, Lupino E, Calvo A, Moglia C, Buccinna B, et al. (2011)
Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS
patients with and without TARDBP mutations. Acta Neuropathol 121:
611–622.
28. Achiron A, Gurevich M (2006) Peripheral blood gene expression signature
mirrors central nervous system disease: the model of multiple sclerosis.
Autoimmun Rev 5: 517–522.
29. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, et al. (2005) Genome-wide
expression profiling of human blood reveals biomarkers for Huntington’s
disease. Proc Natl Acad Sci U S A 102: 11023–11028.
30. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, et al. (2007) Transcriptional
profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging
28: 1795–1809.
31. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP (1996) Avoiding false
positive diagnoses of motor neuron disease: lessons from the Scottish Motor
Neuron Disease Register. J Neurol Neurosurg Psychiatry 60: 147–151.
32. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, et al. (2000) Amyotrophic
lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 57:
109–113.
33. Kraemer M, Buerger M, Berlit P (2010) Diagnostic problems and delay of
diagnosis in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 112: 103–105.
34. Srinivasan J, Scala S, Jones HR, Saleh F, Russell JA (2006) Inappropriate
surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis.
Muscle Nerve 34: 359–360.
35. Staschke KA, Dong S, Saha J, Zhao J, Brooks NA, et al. (2009) IRAK4 kinase
activity is required for Th17 differentiation and Th17-mediated disease.
J Immunol 183: 568–577.
36. Sharp FR, Xu H, Lit L, Walker W, Apperson M, et al. (2006) The future of
genomic profiling of neurological diseases using blood. Arch Neurol 63:
1529–1536.
37. Tang Y, Lu A, Aronow BJ, Sharp FR (2001) Blood genomic responses differ
after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of
disease. Ann Neurol 50: 699–707.
38. Gladkevich A, Kauffman HF, Korf J (2004) Lymphocytes as a neural probe:
potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol
Psychiatry 28: 559–576.
39. Basso M, Samengo G, Nardo G, Massignan T, D’Alessandro G, et al. (2009)
Characterization of detergent-insoluble proteins in ALS indicates a causal link
between nitrative stress and aggregation in pathogenesis. PLoS ONE 4: e8130.
40. Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress:
disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7:
1013–1030.
41. Beckman JS (1996) Oxidative damage and tyrosine nitration from peroxynitrite.
Chem Res Toxicol 9: 836–844.
42. Board PG, Coggan M, Chelvanayagam G, Easteal S, Jermiin LS, et al. (2000)
Identification, characterization, and crystal structure of the Omega class
glutathione transferases. J Biol Chem 275: 24798–24806.
43. Ghezzi P, Casagrande S, Massignan T, Basso M, Bellacchio E, et al. (2006)
Redox regulation of cyclophilin A by glutathionylation. Proteomics 6: 817–825.
ALS Multiprotein Biomarkers in PBMC
PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e2554544. Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, et al. (2008) CLIC1
function is required for beta-amyloid-induced generation of reactive oxygen
species by microglia. J Neurosci 28: 11488–11499.
45. Wood ZA, Schroder E, Robin Harris J, Poole LB (2003) Structure, mechanism
and regulation of peroxiredoxins. Trends Biochem Sci 28: 32–40.
46. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, et al. (1997)
Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral
sclerosis. Ann Neurol 42: 644–654.
47. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, et al. (1997)
Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/
zinc superoxide dismutase mutation. Ann Neurol 42: 326–334.
48. Barber SC, Mead RJ, Shaw PJ (2006) Oxidative stress in ALS: a mechanism of
neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762:
1051–1067.
49. Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, et al. (2007) Oxidative and
endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis.
Brain 130: 3111–3123.
50. Krecic AM, Swanson MS (1999) hnRNP complexes: composition, structure, and
function. Curr Opin Cell Biol 11: 363–371.
51. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, et al. (2005) TDP-
43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal
tail: an important region for the inhibition of cystic fibrosis transmembrane
conductance regulator exon 9 splicing. J Biol Chem 280: 37572–37584.
52. Lemmens R, Moore MJ, Al-Chalabi A, Brown RH, Jr., Robberecht W (2010)
RNA metabolism and the pathogenesis of motor neuron diseases. Trends
Neurosci 33: 249–258.
53. Appel SH, Beers DR, Henkel JS (2010) T cell-microglial dialogue in Parkinson’s
disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 31:
7–17.
54. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, et al. (1999) The
ALSFRS-R: a revised ALS functional rating scale that incorporates assessments
of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:
13–21.
55. Pappin DJ, Hojrup P, Bleasby AJ (1993) Rapid identification of proteins by
peptide-mass fingerprinting. Curr Biol 3: 327–332.
56. Carpi D, Korkalainen M, Airoldi L, Fanelli R, Hakansson H, et al. (2009)
Dioxin-sensitive proteins in differentiating osteoblasts: effects on bone formation
in vitro. Toxicol Sci 108: 330–343.
ALS Multiprotein Biomarkers in PBMC
PLoS ONE | www.plosone.org 13 October 2011 | Volume 6 | Issue 10 | e25545